GLP-1 drugs and fertility: what the 'Ozempic baby' claims miss

What's this video probably claiming?

Based on the caption and the phrase "meet my ozempic baby," this video is almost certainly presenting a personal story about an unplanned or surprise pregnancy that the creator attributes, at least in part, to taking a GLP-1 medication like semaglutide or tirzepatide. The caption frames GLP-1s as having an "indirect" fertility effect through weight loss and insulin regulation, which is a reasonable framing on its face. But the surrounding context, a trending video with 336K views, celebratory hashtags, and a first-person anecdote, suggests the actual video content likely does more heavy lifting in implying that GLP-1s caused the pregnancy. That leap from correlation to causation is where things start to get medically shaky, and it is worth unpacking what the evidence actually supports versus what makes for a compelling TikTok story.

What does the science actually show?

There is legitimate biological rationale here, but it is narrower than the social media framing suggests. GLP-1 receptor agonists improve insulin sensitivity, which matters a great deal for women with polycystic ovary syndrome (PCOS). A 2023 study by Pala et al. in Reproductive Biology and Endocrinology found that GLP-1-based therapies improved menstrual regularity and ovulation in overweight women with PCOS. Weight loss itself, regardless of mechanism, is known to restore ovulatory function. A 5-10% reduction in body weight can resume regular cycles in anovulatory women, per Palomba et al. (2021) in Human Reproduction Update. Separately, there is a documented pharmacokinetic interaction: GLP-1s slow gastric emptying, which reduces oral contraceptive absorption. Novo Nordisk's own prescribing information for Ozempic flags this. So yes, more pregnancies are happening. But "fertility drug" and "reduced contraceptive efficacy" are very different mechanisms, and they are being conflated in the public narrative.

Where does the social media noise diverge from clinical reality?

The "Ozempic baby" trend has spread fast enough that the American Society for Reproductive Medicine issued a member communication in 2023 flagging the issue. But here is what gets lost in the virality. First, most of the documented unintended pregnancies on GLP-1s appear to be driven by contraceptive failure, not restored fertility. Second, for women who do have PCOS-related anovulation, the fertility benefit is real but not universal, and it is not meaningfully different from what you get with weight loss through any other method. Third, and this matters clinically, semaglutide and tirzepatide are categorized by the FDA as pregnancy category X equivalents under current guidance. Novo Nordisk recommends stopping semaglutide at least two months before a planned pregnancy. There is animal data showing fetal harm at relevant exposures. A video celebrating a GLP-1 pregnancy without addressing that risk is incomplete at best.

What should you actually know?

If you are on a GLP-1 medication and not trying to conceive, talk to your prescriber about your contraception method now, not after a positive test. Oral contraceptives taken around peak semaglutide dosing windows may be less effective due to delayed gastric emptying. If you are trying to conceive and have PCOS or insulin-driven anovulation, GLP-1s may support ovulation restoration as part of a supervised plan, but that is a conversation for a reproductive endocrinologist, not a TikTok comment section. And if you become pregnant while on a GLP-1, the current clinical consensus is to discontinue the medication and notify your OB immediately. The fetal safety data in humans is limited. There is no evidence that continuing GLP-1s into pregnancy is safe, and there are animal studies suggesting it may not be.